UPDATE: Impax Laboratories (IPXL) Posts Q3 EPS of 48c; Sees Q4 Revs Down 15% - 20%
Tweet
Share
E-mailGet Alerts IPXL Hot Sheet
Join SI Premium – FREE
(Updated - October 30, 2012 8:20 AM EDT)
Impax Laboratories Inc. (NASDAQ: IPXL) reported Q3 EPS of $0.48, versus the analyst estimate of $0.49. Revenue for the quarter came in at $145.6 million versus the consensus estimate of $160.76 million.
With the recent additional competition on fenofibrate capsules and generic Adderall XR®, the Company expects its total revenues for the fourth quarter of 2012 to decline by approximately 15% to 20% from the third quarter of 2012.
For earnings history and earnings-related data on Impax Laboratories Inc. (IPXL) click here.
Impax Laboratories Inc. (NASDAQ: IPXL) reported Q3 EPS of $0.48, versus the analyst estimate of $0.49. Revenue for the quarter came in at $145.6 million versus the consensus estimate of $160.76 million.
With the recent additional competition on fenofibrate capsules and generic Adderall XR®, the Company expects its total revenues for the fourth quarter of 2012 to decline by approximately 15% to 20% from the third quarter of 2012.
For earnings history and earnings-related data on Impax Laboratories Inc. (IPXL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Sinda raises $331M in IPO, reports Q2 net loss of $16.6M
- Piper Sandler Reiterates Overweight Rating on KKR (KKR), 'highest conviction name'
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
